Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight-based ribavirin exposure

Hepatology

Volumn 48, Issue 3, 2008, Pages 1019-1020

  Yu, Ming Lung ^a,b   Dai, Chia Yen ^a,b   Huang, Jee Fu ^b,c   Chuang, Wan Long ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

AGE; AREA UNDER THE CURVE; BODY WEIGHT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT DURATION; VIREMIA;

ANTIVIRAL AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 51349166802     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22434     Document Type: Letter

References (10)

1. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. HEPATOLOGY 2008;47:43-50.
2. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006;43:954-960.
3. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-460.
4. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097.
5. Rodriguez-Torres M, Sulkowski M, Chung RT, Hamzeh FM, Jensen D. Association of pretreatment and on-treatment factors with rapid virological response in HCV genotype 1-infected patients with peginterferon alfa-2a/ribavirin [Abstract]. HEPATOLOGY 2007;46(Suppl):817A.
6. Yu ML, Dai CY, Huang JF, Chin CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. HEPATOLOGY 2008;47:1884-1893.
7. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559.
8. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. HEPATOLOGY 2008;47:35-42.
9. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; doi:10.1053/j.gastro.2008.04.015. Available at: www.gastrojournal.org.
10. Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. HEPATOLOGY 2008;47:1453-1461.